Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.
Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.
Esperion (NASDAQ: ESPR) granted 260,000 restricted stock units (RSUs) on May 12, 2026 to 23 new employees under its 2017 Inducement Equity Incentive Plan, used exclusively for new hires under NASDAQ Rule 5635(c)(4).
RSUs vest 25% after one year, then 75% in twelve quarterly installments, subject to continued employment.
Esperion (NASDAQ: ESPR) announced two new analyses and three encore presentations on bempedoic acid to be featured at the European Atherosclerosis Society (EAS) Congress 2026, May 24-27 in Athens.
Data include a Phase 2 pediatric HeFH study showing LDL-C reductions and CLEAR Outcomes analyses of factors linked to ≥30% LDL-C lowering and cardiovascular outcomes.
Esperion (Nasdaq: ESPR) agreed to be acquired by funds managed by ARCHIMED for up to approximately $1.1 billion in total equity value on a fully diluted basis. Shareholders will receive $3.16 per share in cash at closing plus a non-tradeable CVR for up to $100 million in contingent milestone payments tied to future U.S. net sales. The upfront cash equals a 58% premium to the April 30, 2026 closing price. The transaction, unanimously approved by the board, is expected to close in Q3 2026, subject to shareholder and regulatory approvals, after which Esperion will become private and its Nasdaq listing will end.
Esperion (NASDAQ: ESPR) will report first quarter 2026 financial results before the market opens on May 7, 2026.
Management will host a live webcast at 8:00 a.m. ET the same day to discuss results and business updates; a replay will be available about two hours after the call and archived for ~90 days.
Esperion (NASDAQ: ESPR) closed its acquisition of Corstasis Therapeutics on April 2, 2026, adding Enbumyst, the first and only FDA‑approved nasal spray loop diuretic. Enbumyst received FDA approval in September 2025 for edema associated with congestive heart failure, hepatic, and renal disease.
The acquisition expands Esperion’s cardiovascular franchise into outpatient, acute‑adjacent care and aims to leverage existing commercial infrastructure to accelerate adoption, payer engagement, and patient access.
Esperion (NASDAQ: ESPR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 9:30 a.m. ET, with a live webcast available on the company investor site. A replay will be posted about two hours after the call and archived for ~90 days.
Esperion is a commercial-stage cardiometabolic biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with approvals in more than 40 countries and an R&D pipeline targeting ACLY biology, Primary Sclerosing Cholangitis, and renal diseases.
Esperion (NASDAQ: ESPR) presented two post-hoc CLEAR Outcomes analyses at ACC.26 (Mar 28-30, 2026) showing clinical benefits of bempedoic acid (NEXLETOL/NEXLIZET). Key findings: a 22% reduced risk of ischemic stroke in statin-intolerant patients and similar MACE risk reduction in patients with autoimmune or inflammatory diseases.
The company highlighted safety considerations including hyperuricemia, gout risk, and a small increased tendon rupture incidence observed in trials.
Esperion (NASDAQ: ESPR) announced two moderated poster presentations from the CLEAR Outcomes trial at the American College of Cardiology 2026 Annual Scientific Session (ACC.26), March 28-30 in New Orleans.
Both analyses evaluate bempedoic acid in underrepresented populations: stroke incidence in statin-intolerant patients and cardiovascular outcomes in patients with autoimmune or inflammatory diseases.
Esperion (NASDAQ: ESPR) announced that bempedoic acid earned multiple Class 1 recommendations in the 2026 ACC/AHA multisociety dyslipidemia guideline (published March 16, 2026), including for patients with statin intolerance, severe hypercholesterolemia, and selected primary and secondary prevention groups.
The guideline places bempedoic acid alongside ezetimibe and PCSK9 mAb after statins, reintroduces LDL-C targets, and supports earlier combination oral therapy to reduce ASCVD risk.
Esperion (NASDAQ: ESPR) reported FY2025 total revenue of $403.1M (21% Y/Y) and Q4 revenue of $168.4M (144% Y/Y). U.S. net product revenue grew ~38% Y/Y to $159.6M for FY2025. The company announced an agreement to acquire Corstasis and Enbumyst™, and strengthened patent settlements and payer coverage.
Key financials: Q4 U.S. product sales $43.7M, collaboration revenue driven by a $90M Otsuka payment, FY net loss $22.7M, cash $167.9M, and 2026 operating expense guidance of $225M–$255M.